Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vitrafy Life Sciences Ltd. ( (AU:VFY) ) just unveiled an update.
Vitrafy Life Sciences Limited has successfully completed Phase 1 of a blood platelet study with the US Army Institute of Surgical Research, demonstrating the efficacy of its cryopreservation technology. The study showed that the preserved blood platelets maintained high post-thaw recoveries and functionality, exceeding regulatory standards, which positions Vitrafy to advance to the next phase of the project and begin commercial discussions. This development highlights the potential for Vitrafy’s technology to address critical blood supply needs in trauma settings, both in military and civilian environments.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited operates in the life sciences industry, focusing on cryopreservation technology. The company specializes in developing processes and protocols for preserving biological materials, such as blood platelets, for military and civilian applications.
YTD Price Performance: -27.65%
Average Trading Volume: 28,507
For detailed information about VFY stock, go to TipRanks’ Stock Analysis page.